If your child is struggling with their weight and you've heard about medications like Wegovy or Saxenda, you're probably wondering: does my child actually qualify?
It's a fair question, and one that more parents are asking every month. GLP-1 medications have been in the news constantly, but most of the coverage focuses on adults. The rules for adolescents are different, and the information can be hard to find in plain language.
This guide breaks down exactly who is eligible, what the FDA has approved, and what a responsible treatment program looks like for young patients.
What are GLP-1 medications?
GLP-1 (glucagon-like peptide-1) receptor agonists are injectable medications that mimic a natural hormone your body already produces. This hormone tells the brain "I'm full," slows digestion, and helps regulate blood sugar. When given as a medication, it helps reduce appetite and supports meaningful weight loss.
These drugs were originally developed for type 2 diabetes but have since been approved specifically for weight management, including in adolescents.
Which GLP-1 medications are FDA-approved for adolescents?
As of 2026, two GLP-1 medications are FDA-approved for chronic weight management in patients aged 12 and older:
Wegovy (semaglutide)
- Once-weekly injection
- FDA-approved December 2022
- 16.1% average BMI reduction (STEP TEENS trial)
- Based on: NEJM 2022
Saxenda (liraglutide)
- Daily injection
- FDA-approved December 2020
- ~5% average BMI reduction
- Based on: SCALE Teens trial
Ozempic is the same molecule as Wegovy (semaglutide) but is approved only for type 2 diabetes, not weight management in adolescents.
Zepbound (tirzepatide) is approved for adult weight management but is not yet approved for adolescents for obesity. Its sister drug Mounjaro was approved in February 2026 for type 2 diabetes in children aged 10+, a different indication.
The eligibility criteria: does my child qualify?
Based on FDA labeling and the American Academy of Pediatrics (AAP) Clinical Practice Guideline published in January 2023, the general eligibility criteria are:
Age requirement
Your child must be 12 years of age or older. No GLP-1 medications are currently approved for weight management in children under 12.
BMI requirement
Your child must have obesity, defined as a BMI at or above the 95th percentile for their age and sex. For adolescents, BMI is plotted on growth charts that account for normal developmental variation, it is not the same as the adult BMI scale.
| Classification | BMI percentile |
|---|---|
| Healthy weight | 5th to 84th percentile |
| Overweight | 85th to below 95th percentile |
| Class 1 Obesity | ≥95th percentile |
| Class 2 Obesity (Severe) | ≥120% of the 95th percentile |
| Class 3 Obesity (Severe) | ≥140% of the 95th percentile |
According to CDC data (June 2025), 83% of adolescent GLP-1 prescriptions in 2023 went to patients with severe obesity.
Find your teen's BMI percentile with our free calculatorFor Saxenda specifically, the FDA label also requires that the adolescent weigh more than 60 kg (approximately 132 lbs) and have a BMI that would correspond to adult obesity (≥30 kg/m²) using international cut-off values.
The AAP guideline recommends that clinicians offer weight-loss pharmacotherapy to adolescents aged 12 and older with obesity, particularly when obesity is accompanied by medical complications such as prediabetes, high blood pressure, sleep apnea, or fatty liver disease.
What the research shows
The strongest evidence for adolescent GLP-1 treatment comes from the STEP TEENS trial, published in the New England Journal of Medicine in December 2022. The study enrolled 201 adolescents aged 12–17 with obesity and found:
16.1%
Average BMI reduction over 68 weeks with semaglutide + lifestyle intervention
+0.6%
BMI change in placebo group (lifestyle intervention only) over same period
Source: Weghuber et al., NEJM 2022 (STEP TEENS trial)
The SCALE Teens trial for liraglutide (Saxenda) showed more modest results, approximately 5% BMI reduction, but still demonstrated meaningful benefit compared to placebo.
Why medication alone is not enough
Every clinical trial that produced these results paired medication with a structured lifestyle program. The AAP guideline is explicit: pharmacotherapy should be offered "as an adjunct to health behavior and lifestyle treatment", not as a standalone solution.
What does that mean in practice? A comprehensive program should include:
Medical supervision
Regular monitoring by a physician experienced in adolescent weight management, including dose adjustments and safety labs.
Personalized nutrition
Not a generic diet plan, but nutrition guidance designed for young bodies that are still developing.
Physical activity planning
Age-appropriate movement goals that build sustainable habits.
Behavioral support
Addressing the emotional and psychological dimensions of weight, including food relationships and habit formation.
Ongoing monitoring
Tracking not just weight, but growth, development, and overall health markers over time.
This is the difference between a prescription and a program. The research is clear: the best outcomes come from combining medication with comprehensive support.
The access gap: why so few eligible adolescents are getting treatment
Despite the evidence, remarkably few eligible adolescents are actually receiving treatment. A CDC study published in June 2025 found that even after a 300% increase in prescribing following the AAP guideline and FDA approvals, fewer than 1% of adolescents with obesity were prescribed a GLP-1 medication in 2023.
The barriers are real:
Cost and insurance coverage
Without insurance, Wegovy can cost over $1,300 per month. Many insurance plans still do not cover anti-obesity medications for adolescents.
Provider awareness
Many pediatricians are not yet comfortable prescribing these medications, and referral pathways to obesity medicine specialists are limited.
Geographic access
Families in rural areas or underserved communities often have no local providers trained in adolescent obesity medicine.
Racial and socioeconomic disparities
CDC data shows that Black adolescents were significantly less likely to receive prescriptions than White adolescents, even after controlling for obesity severity.
Common side effects parents should know about
GLP-1 medications are generally well-tolerated in adolescents, but side effects do occur, especially during the initial dose-titration period. The most common include:
- • Nausea (the most frequently reported)
- • Vomiting
- • Stomach discomfort or cramping
- • Diarrhea or constipation
- • Decreased appetite
These symptoms typically improve within the first few weeks as the body adjusts, particularly when the dose is increased gradually. Serious side effects are rare but can include pancreatitis and gallbladder problems, which is why medical supervision throughout treatment is essential.
Wondering if this applies to your child? The 2-minute eligibility check tells you if Thryvwell could be a fit. No commitment, no payment info.
Questions to ask your child's doctor
How Thryvwell approaches adolescent GLP-1 treatment
At Thryvwell, we built our program specifically for patients aged 12–26 because we believe this population deserves more than a prescription and a "good luck."
Our approach includes:
- • Board-certified pediatric specialists who understand how GLP-1 medications interact with young, still-developing bodies
- • A structured preparation phase before any medication begins, ensuring your child is physically and behaviorally ready
- • Personalized nutrition and activity planning designed for young bodies, not adapted from adult programs
- • Behavioral support that addresses the emotional dimensions of weight
- • Ongoing medical monitoring including growth tracking, lab work, and regular check-ins
- • 100% virtual delivery, no waiting rooms, no missed school
We're not following the new standard of care. We're setting it.
Currently accepting founding patients · Ages 12–26 · Referred by pediatricians
Sources
- Kompaniyets L, et al. "Prescriptions for Obesity Medications Among Adolescents Aged 12–17 Years with Obesity, United States, 2018–2023." MMWR, CDC. June 5, 2025.
- Hampl SE, et al. "Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents with Obesity." Pediatrics, American Academy of Pediatrics. January 2023.
- Weghuber D, et al. "Once-Weekly Semaglutide in Adolescents with Obesity." New England Journal of Medicine. December 2022.
- Kelly AS, et al. "A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity." New England Journal of Medicine. 2020.
- Lurie Children's Hospital. "GLP-1 Medications for Obesity: A Parent's Guide." July 2026.
- Stanford Medicine. "GLP-1s 101: What the science says about weight loss, side effects, safety." June 2026.
This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any medication for your child.
Thryvwell provides doctor-supervised GLP-1 weight management for patients aged 12–26. Referred by pediatricians. Learn more at thryvwellhealth.com.
